Ablynx announced that it will present two posters on its novel anti-IL-6R Nanobody®, ALX-0061, at the 2014 American College of Rheumatology (ACR/ARHP) Annual Meeting, which is taking place from 14 to 19 November 2014 in Boston, MA, USA.
Ablynx announced that it will present two posters on its novel anti-IL-6R Nanobody®, ALX-0061, at the 2014 American College of Rheumatology (ACR/ARHP) Annual Meeting, which is taking place from 14 to 19 November 2014 in Boston, MA, USA.
The first poster presentation will include results from a post-hoc analysis of data collected in a 24-week combined Phase I/II study in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate. These data show that, in patients with established RA, intravenously administered ALX-0061 induces and maintains remission as assessed by both DAS28 criteria and the more stringent Boolean remission definition. These results suggest that ALX-0061 has the potential for disease modifying activity, which supports treat-to-target management of RA.
The abstract “Impact of Clinical Remission on Physical Function in Patients with Rheumatoid Arthritis Treated with ALX-0061: Post-hoc Analysis of Phase I/II Data” is available on the ACR website at http://www.acrannualmeeting.org/ (Abstract No. 1479; Poster Presentation #1454 on Monday 17 November 2014) and shortly after the presentation, the poster will be available on Ablynx’s corporate website (via this link).
The second poster presentation will include data from in vitro experiments that assessed the biological activity and affinity of ALX-0061 for both the soluble and membrane-bound IL-6-receptor as compared to tocilizumab (Actemra®). The in vitro results support the preferential inhibition of soluble IL-6R trans-signalling by ALX-0061, which may result in a more favourable benefit-risk profile compared to tocilizumab.
The abstract “ALX-0061, an anti-IL-6R Nanobody for use in rheumatoid arthritis, demonstrates a different in vitro profile as compared to tocilizumab” is available on the ACR website at http://www.acrannualmeeting.org/ (Abstract No. 1498; Poster Presentation #1473 on Monday 17 November 2014) and shortly after the presentation, the poster will be available on Ablynx’s corporate website (via this link).
